Harriet M. Kluger
Yale New Haven Hospital
1 paper in the Anchorcite directory, published in 2013, cited 4,287 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 1 paper
- Immunotherapy and Immune Responses · 1 paper
- Cutaneous Melanoma Detection and Management · 1 paper
Frequent co-authors
- Jedd D. Wolchok · 1 paper
- Margaret K. Callahan · 1 paper
- Michael Andrew Postow · 1 paper
- Naiyer A. Rizvi · 1 paper
- Alexander M. Lesokhin · 1 paper
- Neil Howard Segal · 1 paper
- Charlotte Eielson Ariyan · 1 paper
- RuthAnn Gordon · 1 paper
Papers
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2013 · 4,287 citations
BACKGROUND: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis…
Metadata from OpenAlex (CC0).